Among initiators of GLP1 receptor agonists versus SGLT2 inhibitors, the direction of effect modification by age in two prior studies [16, 25] was conflicting, and the direction of effect modification by cardiovascular disease and sex in our study disputes prior evidence [16, 25]. The gene discussed is SLC5A2; the disease is cardiovascular disorder.